Study on the Expression of KDM6B of Osteoblast in Diabetic Environment

TANG Yu, HU Yun, LUO Dan, DING Xiao-qian, LI Cai-yu, ZHENG Lei-lei

Abstract

To investigate the ability of osteogenic differentiation and the expression of histone demethylases KDM6B in bone marrow mesenchymal stem cells (BMSCs) in diabetic environment.  Methods  Diabetic model rats was successfully established, and BMSCs from diabetic model rats and normal rats were isolated and cultured for further study. When cultured cells, we added high concentration of glucose and advanced glycosylation products (AGE) in the medium to imitating the diabetic environment. BMSCs were divided into 6 groups: diabetes group (derived from diabets SD rats), normal group (derived from normal SD rats), high glucose group (30 mmol/L D-glucose), normal glucose group (5.5 mmol/L D-glucose), AGE group (AGE 300 μg/mL) and BSA group (BSA 300 μg/mL). BMSCs in diabetes group were derived from diabetes SD rats, while others were derived from normal SD rats. After 7 d of osteogenic induction, the cells were examined the ability of osteogenic differentiation by alkaline phosphatase (ALP) staining, the transcription levels of Runt-related transcription factor 2 (Runx2) and KDM6B were determined by RT-PCR, and the expression levels of H3K27Me3 protein were examined by Western bolt.  Results  Compared with the control groups, the numbers of ALP stained cells and the mRNA levels of Runx2 and KDM6B in diabetes group, high glucose group and AGE group were all decreased (P < 0.05), while H3K27Me3 protein expression levels were all increased (P < 0.05).  Conclusion  The ability of osteogenic differentiation of BMSCs in diabetic environment was weakened, and the expression of Runx2 mRNA was inhibited, which may be related to the increased expression of H3K27Me3 after the inhibition of KDM6B expression.

 

Keywords: Diabetes, Osteoblast, Epigenetics, KDM6B

 

Full Text:

PDF


References


TSENTIDIS С, GOURGIOTIS D, KOSSIVA L, et al. Increased levels of Dickkopf-1 are indicative of Wnt/p-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density. Osteoporos Int, 2017, 28 ( 3) : 945-953.

HU Z. MA C, LIANG Y, et al. Osteoclasts in bone regeneration under type 2 diabetes mellitus. Acta Biomater. 2019,84;402-413[2019-01-06]. https://doi. org/10. 1016/j. actbio. 2018. 11.052.

ESTELLER M. Cancer epigenetics for the 21st century: what’s next. Genes Cancer,2011,2(6);604-606.

DENG P, CHEN Q M, HONG C, et al. Histone methyltransferases and demethylases: regulators in balancing osteogenic and adipogenic differentiation of mesenchymal stem cells. Int J Oral Sci .2015 .7(4): 197-204.

QIAN С, ZHU С, YU W. et al. Bone morphogenetic protein 2 promotes osteogenesis of bone marrow stromal cells in type 2 diabetic rats via the Wnt signaling pathway. Int J Biochem Cell Biol, 2016, 80: 143-153[2019-01-06]. https:// doi. org/10. 1016/j. biocel. 2016. 09. 025.

CHENG Y Z. YANG S L, WANG J Y, et al. Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sci,2018,205; 184-192[2019-01-06]. httpss// doi. org/10. 1016/j. Ifs. 2018. 04. 042.

KUME S, КАТО S, YAMAGISHI S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res, 2005, 20 ( 9 ); 1647- 1658.

PHIMPHILAI M, POTHACHAROEN P, KONGTAWELERT P, et al. Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes. J Bone Miner MetaD,2017,35(6);631 -641.

YE L. FAN Z. YU B, et al. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell,2012,11(1):50-61.

WANG C, WANG J, LI J, et al. К DM 5 A controls bone morphogenic protein 2-induced osteogenic differentiation of bone mesenchymal stem cells during osteoporosis. Cell Death Dis,2016,7( 8): e2335[2019-01-06]. https;//www. nature. com/articles/cddis2016238. doi; 10. 1038/cddis. 2016. 238.

CHENG Y, YUAN Q, VERGNES L, et al. К DM IB protects against obesity and metabolic dysfunction. Proc Natl Acad Sci U S A, 2018,115(24); E5566-E5575[2019-01-06]. https://doi. org/10. 1073/pnas. 1721811115.


Refbacks

  • There are currently no refbacks.